<DOC>
	<DOCNO>NCT00578149</DOCNO>
	<brief_summary>This study do learn effect ( good bad ) bevacizumab conjunction carboplatin/paclitaxel radiation therapy patient non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Bevacizumab Carboplatin/Paclitaxel Radiation Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>- There three phase treatment 1 ) chemoradiation , 2 ) consolidation 3 ) maintenance therapy . - The chemoradiation phase week 1 week 7 . The following occur phase : Daily chest radiation start day 1 ; pre-medication paclitaxel ; weekly intravenous administration paclitaxel carboplatin ; intravenous administration bevacizumab weekly every three week start day 1 . - During week 8-9 , patient undergo PET/CT scan restaging . - The consolidation phase week 10 week 16 . The following occur phase : Pre-medication paclitaxel ; intravenous administration paclitaxel carboplatin twice weekly every 3 week ; intravenous administration bevacizumab weekly every 3 week . - The maintenance phase week 17 week 52 . The following occur phase ; intravenous administration bevacizumab week every three week 1 year ; PET/CT scan every three month . - The following evaluation occur treatment : 1 ) Patients evaluated weekly study doctor , 2 ) Weight , difficulty discomfort swallow , shortness breath well-being record , 3 ) Weekly lab test include CBC , chemistry , liver function test . 4 ) Followed cycle chemotherapy every 6-8 week duration study . - The following evaluation occur treatment : 1 ) Every 6-8 week assess response CT PET/CT scan one year , 2 ) Toxicity also assess follow-up interval .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm nonsmall cell lung cancer ( NSCLC ) evaluate determined candidate surgical resection part definitive management stage III disease . Age 18 year old ECOG performance status 01 Life Expectancy great six month Normal organ marrow function Women men childbearing potential must agree use adequate contraception Prior chemotherapy thoracic radiation therapy Squamous histology histology close proximity major vessel Active hemoptysis History hypercoagulability Known distant metastatic disease History allergic reaction attribute compound similar chemical biological composition bevacizumab , carboplatin , paclitaxel agent use study Patients uncontrolled intercurrent illness Pregnant woman Major surgical procedure , open biopsy , significant traumatic injury 28 day prior day 0 Minor surgical procedure within 7 day day 0 HIVpositive patient receive combination antiretroviral therapy . Nonskin cancer malignancy past 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>chemoradiotherapy</keyword>
	<keyword>Lung cancer</keyword>
</DOC>